EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches

Shabnam Eghbali iD, Thatcher Ross Heumann

Cancers · 13.01.2025 · 17 (2) · 236

DOI: 10.3390/cancers17020236 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 13.01.2025. Verfasst von Shabnam Eghbali und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institute of Health (USA), Conquer Cancer Young Investigator.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, and, with only 15–20% of HCC patients being suitable for potentially curative treatments, the vast majority of patients with HCC ultimately require systemic therapy. For decades, the choice of effective systemic therapy for HCC remained sparse. In recent years, after the combination of atezolizumab and bevacizumab demonstrated superior overall survival over the first-line standard, sorafenib, there has been a major therapeutic paradigm shift to immunotherapy-based regimens for HCC. While representing a great leap forward for the treatment of this cancer, the reality is that less than one-third of patients achieve an objective response to immune checkpoint inhibitor-based therapy, so there remains a significant clinical need for further therapeutic optimization. In this review, we provide an overview of the current landscape of immunotherapy for unresectable HCC and delve into the tumor intrinsic and extrinsic mechanisms of resistance to established immunotherapies with a focus on novel therapeutic targets with strong translational potential. Following this, we spotlight emerging immunotherapy approaches and notable clinical trials aiming to optimize immunotherapy efficacy in HCC that include novel immune checkpoint inhibitors, tumor microenvironment modulators, targeted delivery systems, and locoregional interventions.

Schlagwörter

Stichwörter der Autor:innen

CAR-T cell therapyWnt/β-cateninangiogenesisbispecific antibodiescancer vaccineglypican-3hepatocellular carcinomaimmunotherapylocoregional therapyneoadjuvant

Autor:innen und Institutionen

  • Division of Internal Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA.

ORCID-Profile: Shabnam Eghbali

Förderung

  • NCI NIH HHS
  • National Institute of Health (USA)
  • Conquer Cancer Young Investigator

Zitieren

APA

Eghbali, S., & Heumann, T. R. (2025). Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches. Cancers, 17(2), 236. https://doi.org/10.3390/cancers17020236

Vancouver

Eghbali S, Heumann TR. Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches. Cancers. 2025;17(2):236. doi:10.3390/cancers17020236

BibTeX
@article{Eghbali2025,
  author = {Eghbali, Shabnam and Heumann, Thatcher Ross},
  title = {Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {2},
  pages = {236},
  doi = {10.3390/cancers17020236}
}
Kostenlos starten →